BACKGROUND: Venous thromboembolism (VTE) is a serious complication of cancer and its treatment. The current study assessed the risk and clinical predictors of VTE in breast cancer patients by time since diagnosis. METHODS: This Swedish population-based study included 8338 breast cancer patients diagnosed from 2001 to 2008 in the Stockholm-Gotland region with complete follow-up until 2012. Their incidence of VTE was compared with the incidence among 39,013 age-matched reference individuals from the general population. Cox and flexible parametric models were used to examine associations with patient, tumor, and treatment characteristics, accounting for time-dependent effects. RESULTS: Over a median follow-up of 7.2 years, 426 breast cancer patients experienced a VTE event (cumulative incidence, 5.1%). The VTE incidence was 3-fold increased (hazard ratio [HR], 3.28; 95% confidence interval [CI], 2.87-3.74) in comparison with the incidence in the general population and was highest 6 months after diagnosis (HR, 8.62; 95% CI, 6.56-11.33) with a sustained increase in risk thereafter (HR at 5 years, 2.19; 95% CI, 1.80-2.67). Independent predictors of VTE included the following: older age, being overweight, preexisting VTE, comorbid disease, tumor size > 40 mm, progesterone receptor (PR)-negative status, more than 4 affected lymph nodes, and receipt of chemo-and endocrine therapy. The impact of chemotherapy was limited to early-onset VTE, whereas comorbid disease and PR-negative status were more strongly associated with late-onset events. CONCLUSIONS: This study confirms the long-term risk of VTE in breast cancer patients and identifies a comprehensive set of clinical risk predictors. Temporal associations with patient, tumor, and treatment characteristics provide insight into the timedependent etiology of VTE. Cancer 2017;123:468-75.
INTRODUCTION
Venous thromboembolism (VTE) is a major health problem affecting approximately 1 to 2 individuals per 1000 per year. 1, 2 Breast cancer patients are at 3-to 4-fold increased risk of developing VTE in comparison with women without cancer. 3, 4 Although the absolute risk of VTE is relatively low for breast cancer patients in comparison with other cancer populations, the long-term consequences in terms of morbidity 5, 6 and quality of life 7 are substantial, especially for nonmetastatic patients, who have a rather good prognosis. Moreover, as one of the most common cancers, breast cancer contributes to a large number of cancer-related VTE cases and associated health care costs. 8 Several studies have examined the incidence of VTE in breast cancer patients, 3, 4, 9, 10 and all have shown an excess VTE risk shortly after diagnosis along with a potentially sustained increase in risk thereafter. 4 The risk of VTE increases with advanced clinical stages, 3, 4, 9 and randomized clinical trials have reported higher VTE rates during treatment with chemo-and endocrine therapy. [11] [12] [13] Few studies, however, have assessed the independent contributions of tumor, treatment, and other patient-related factors and little is known about predictors of early-onset versus late-onset events. Chemotherapy, for instance, has been suggested to influence short-term risk only, 10, 14, 15 whereas tumor-specific factors associated with locoregional recurrence and distant metastasis 16, 17 may have a larger impact on long-term VTE risk because of the close interrelation between cancer progression and activation of the coagulation system. 18, 19 The identification of time-dependent risk factors is also relevant for the timing of preventive strategies, including early detection and short-term prophylaxis covering periods of highest risk.
In the current study, we aimed to assess the risk and predictors of VTE in a population-based breast cancer cohort by time since diagnosis. We studied the impact of routinely available clinical parameters that could easily be incorporated into future risk-stratification models.
MATERIALS AND METHODS

Breast Cancer Cohort
Our source population comprised women diagnosed with primary invasive breast cancer between 2001 and 2008 in the Stockholm-Gotland region; they were identified through the Stockholm Breast Cancer Register. The register is approximately 99% complete and provides detailed information on tumor and treatment characteristics, and routine follow-up for locoregional recurrences and distant metastases. 20 For the current study, we included patients diagnosed between the ages of 25 and 75 years without distant metastasis at the time of diagnosis (n 5 8338). The cohort was linked by the unique personal identity number to the Cancer Register, Patient Register, Causeof-Death Register, and Total Population Register, and follow-up was complete until December 31, 2012. We also performed linkage with the Prescribed Drug Register, which contains data on all drugs dispensed from Swedish pharmacies from July 2005 onward. Self-reported information on weight and height (from which the body mass index was calculated) was available for a subset of 4687 patients who were invited in 2009 to participate in Libro-1, a study aimed at identifying risk and prognostic factors for breast cancer. 21 The study was approved by the regional ethical review board in Stockholm, and all Libro-1 participants gave written informed consent.
Age-Matched Reference Individuals
We assembled a comparison cohort based on the Total Population Register with crosslinkage to the Cancer Register, Patient Register, Cause-of-Death Register, and Prescribed Drug Register. The Total Population Register contains information on the area of residence, vital status, and dates of immigration and emigration for all Swedish residents. For each patient, we randomly sampled up to 5 women, matched by birth year, from the general population living in the Stockholm-Gotland region. Each reference individual was alive and free of breast cancer on the date of the matched patient's diagnosis (the index date). In total, 2677 women could not be matched to an index case, leaving 39,013 age-matched reference individuals for the analyses. The latest crosslinkage of the Total Population Register to the different health registers was performed on December 31, 2010. Hence, follow-up was shorter for the matched cohort analysis (breast cancer cohort and age-matched population cohort) than the caseonly analysis (breast cancer cohort).
VTE
VTE events were identified through the Patient Register which contains data on all inpatient hospitalizations in Sweden (with nationwide coverage since 1987). 22 From 2001, Swedish counties are also obliged to report hospital-based outpatient physician visits. VTE was defined as a diagnosis of deep vein thrombosis or pulmonary embolism according to International Classification of Diseases codes as described previously 23 (Supporting Table 1 [see online supporting information]). The definition of deep vein thrombosis included diagnoses of lower and upper extremity thrombosis as well as thrombosis in other specified veins, including those of the thorax and abdomen.
Clinical Characteristics
The following variables were extracted from the Stockholm Breast Cancer Register: tumor size, histological grade, estrogen receptor (ER)/progesterone receptor (PR) status, number of affected lymph nodes, type of surgery, radiotherapy, and receipt of chemo-and endocrine therapy. All referred to the date of the primary cancer. Tumor and treatment information was essentially complete (<5% of the patients had missing data) except for the ER status (7.3% missing) and the PR status (8.9% missing). Histological grade was routinely collected from 2004 onward and was missing for 39.3% of the patients. VTE events before the index date were identified through the Patient Register. Comorbid conditions were also extracted and summarized using the Charlson Comorbidity Index score. 24 
Statistical Analyses
We first assessed the risk of VTE in breast cancer patients versus age-matched reference individuals in the matched cohort analysis. The number of person-years at risk was calculated from the index date (i.e., diagnosis date for breast cancer patients) until the date of the first VTE event, death, emigration, or December 31, 2010, whichever came first. Cumulative incidences were visualized with Kaplan-Meier plots. Because of the time-dependent risk pattern, time-specific hazard ratios (HRs) were estimated with flexible parametric survival models (FPMs) 25 with time since index date as the underlying time scale. The FPM uses a restricted cubic spline function to model the baseline hazard and is similar to the Cox proportional hazards model in that it provides an HR as measure of association. A key advantage of the FPM approach is that nonproportional hazards can easily be fitted by the addition of a spline for the interaction with time.
Next, we studied the impact of patient, tumor, and treatment characteristics in a case-only analysis using Cox proportional hazards models. Person-time was defined as described previously and started from the date of diagnosis but included extended follow-up (until December 31, 2012) because this analysis concerned breast cancer patients only. Proportional hazards assumptions were verified with tests for Schoenfeld residuals, and in case of nonproportionality, time-dependent effects were modeled with an FPM. We conducted 3 analyses to study the impact of each clinical parameter: 1) a model adjusted for the age at diagnosis; 2) 3 grouped models including all patient, tumor, and treatment characteristics, respectively, with an additional adjustment for the age at diagnosis; and 3) a multivariable model including all variables.
Three sensitivity analyses were performed. First, we repeated the matched cohort analysis with a more refined outcome definition for patients diagnosed after July 2005. To increase specificity, we included only VTE diagnoses followed by a prescription of vitamin K antagonists (Anatomical Therapeutic Chemical B01AA) or heparins (Anatomical Therapeutic Chemical B01AB) within 90 days or by death within 30 days of the VTE event. A second sensitivity analysis was performed to evaluate the long-term risk associated with the first primary tumor. For this analysis, person-time was additionally censored at events of locoregional recurrence, distant metastasis and a diagnosis of new primary breast cancer. Finally, we repeated all analyses for patients not having preexisting VTE.
RESULTS
Descriptive characteristics of the breast cancer and agematched population cohorts are summarized in Table 1 . The mean age at the diagnosis of breast cancer was 57.1 years, and 426 patients experienced a VTE event during a median follow-up of 7.2 years. The mean age at the diagnosis of VTE was lower for breast cancer patients (62.0 years) than for the age-matched reference individuals (65.3 years). The 1-, 2-, and 5-year cumulative incidences of VTE in the breast cancer cohort were 2.0%, 2.5%, and 4.0%, respectively. Corresponding cumulative incidences in the age-matched reference cohort were 0.3%, 0.5%, and 1.1%, respectively (Fig. 1 ). The VTE rates were 7.9 per 1000 person-years for the breast cancer cohort and 2.4 per 1000 person-years for the age-matched reference individuals (Supporting Table 2 thrombosis and pulmonary embolism resulted in HRs of similar magnitude. Table 3 lists the HRs for VTE by patient, tumor, and treatment characteristics. An older age at diagnosis, a body mass index 25 kg/m 2 , preexisting VTE, a tumor size > 40 mm, PR-negative disease, more than 4 affected lymph nodes, and chemotherapy were all associated with an increased VTE risk in multivariable analyses. Models with stepwise adjustments showed that the impact of patient, tumor, and treatment characteristics was robust except for comorbidities and breast-conserving surgery, which showed no association with VTE in multivariable analyses.
The proportional hazards assumption was met for all variables, except for comorbid disease, PR status and chemotherapy. (Fig. 2 and Supporting Table 3 [see online supporting information]). Though not reaching significance in terms of overall VTE risk, comorbid conditions were associated with late-onset events occurring 5 years after diagnosis. Similarly, PR-negative tumors showed a stronger association with late-onset VTE. Chemotherapy, on the other hand, was associated only with events occurring within the first year after diagnosis.
No major difference in risk was observed between chemotherapy alone and combined chemo-and endocrine therapy. VTE risks were also similar when we compared tamoxifen with aromatase inhibitors (AIs) alone, but AI use tended to show a stronger association with VTE when combined with chemotherapy (Supporting Table 4 [see online supporting information]).
Sensitivity analyses using a more refined definition generated somewhat lower VTE rates but HRs consistent with those observed in the main analysis (Supporting Table 5 [see online supporting information]). The long-term VTE risk remained present when we censored person-time at disease recurrence and new breast cancer diagnoses; that is, the risk associated with the primary tumor was only slightly attenuated 7 years after diagnosis with an HR of 1.76 (Supporting Table 6 [see online supporting information]). The relative risks of VTE were also similar in analyses excluding patients with a VTE history (Supporting Table 7 [see online supporting information]), as were associations with individual patient, tumor, and treatment characteristics (Supporting Table  8 [see online supporting information]).
DISCUSSION
In this population-based study, we demonstrate that breast cancer patients are at highest VTE risk within the first year of diagnosis, but a 2-fold increased risk remains for many years afterward. An older age at diagnosis, being overweight, a history of VTE, comorbid conditions, a larger tumor size, PR-negative disease, lymph node involvement, and receipt of chemo-and endocrine therapy were all independent predictors of VTE in breast cancer patients. The impact of most predictors was constant over time except for chemotherapy, comorbid disease, and PR status, which showed differential associations with earlyonset and late-onset events. Consistent with previous reports, 3,4,9 the incidence of VTE was highest in the first 6 to 12 months after diagnosis. The observed absolute risks are also similar to recent estimates, reported by Walker et al, 10 using UK healthcare data. Long-term risk estimates, however, are scarce, although a Danish study 4 previously indicated a potentially sustained increase in risk, with HRs being significant beyond the first 2 years after diagnosis. Our study is the first to confirm the long-term risk of VTE in breast cancer patients, with relative risks remaining 2-fold increased for at least 7 years. Importantly, we could address the impact of the primary tumor because treatment of recurrent disease can result in inflated long-term risk estimates.
The strong impact of chemotherapy on VTE risk is consistent with previous reports showing an excess risk in chemotherapy-treated patients independent of cancer site and stage. 4, 9, 26, 27 Several mechanisms have been proposed for the high thrombogenic potential of chemotherapy; they include damage to endothelial cell walls, decreased fibrinolytic activity of the blood, and the use of venous catheters for chemotherapy administration. 28, 29 In line with randomized clinical trial data 12, 30 and observational data from Walker et al, 10 the effect of chemotherapy was limited to the period of active treatment. A higher VTE incidence was also found with endocrine therapy. Trials comparing tamoxifen with AIs have reported higher VTE rates with tamoxifen use. 13 In this observational study, no difference by type of endocrine treatment was found, although there was some tendency for a higher VTE risk with AI use in chemotherapy-treated patients. This could be the result of a higher baseline risk in postmenopausal AI users 10 and/or preferential prescriptions of AIs to patients for whom tamoxifen is contraindicated because of a personal/family history of thrombosis or other VTE risk factors. 31 The exact mechanisms underlying the potential higher risk of VTE in AI users who received chemotherapy requires further investigation.
Markers of tumor aggressiveness have previously been linked to VTE risk, 3, 10 but little is known about the independent contribution of tumor-specific factors after one has accounted for treatment effects. We found a positive association with tumor size and PR-negative disease in multivariable analyses. Because both factors are established markers of disease recurrence, 16, 17 these data agree with a close interplay between tumor progression and prothrombotic processes. 18, 19 The lack of an association with ER status can be explained by the adverse effect of endocrine therapy, which might have offset a protective effect of ER-positive disease. Interestingly, the impact of PRnegative tumors was stronger for late-onset VTE. Although the nature of this temporal association remains to be determined, the absence of PR has been associated with resistance to endocrine therapy. 32 ER-positive/PR-negative tumors are further characterized by more aggressive features and worse outcomes in comparison with ER-positive/PR-positive tumors. 33 Previous studies have also reported increased VTE rates with lymph node involvement, 3, 10 but the predictive value of this tumor characteristic has been questioned because of a lack of adjustment for chemotherapy. 34 Despite the slight attenuation in multivariable analyses, extensive nodal involvement remained an independent predictor of VTE in our study.
We further observed independent associations with older age and increasing body mass index, which have been reported previously. 3, 4, 10 Comorbid disease also predicted VTE risk, but only 5 years after diagnosis. Because short-term VTE risk is strongly influenced by breast cancer therapy with treatment options depending on comorbidity burden, this might have masked an independent effect of comorbid disease early after disease onset. The lack of a gradual increase in VTE risk with an increasing comorbidity burden further suggests that specific conditions are likely to have a stronger influence than an aggregated score.
Thromboprophylaxis leads to a reduction in VTE incidence in cancer patients 35, 36 but is not recommended on a routine basis in breast cancer patients because of the low baseline risk and the side effects associated with thromboprophylaxis, namely, bleeding. 37 Selected highrisk patients, however, could potentially benefit from prophylactic or early detection measures. Several riskprediction models have been developed for identifying high-risk patients; the most established is the Khorana model. 38 Although this model includes the cancer site, it does not account for cancer-specific risk factors. Because VTE risk profiles differ by cancer site, 10, 39 cancer-specific models are needed to optimize risk assessment. The clinical predictors identified in our study may thus facilitate future risk stratification in the breast cancer setting. Further studies, however, are required to assess the added value of other laboratory parameters, such as leukocytosis and thrombocytosis, on top of the risk predictors identified here.
The current study benefited from a large population-based design and linkage to register-based data, which minimize information bias. Other strengths are the detailed information on patient, tumor, and treatment characteristics and the use of FPMs for capturing time-dependent effects. We also acknowledge several limitations. Although the Patient Register has high validity for cardiovascular diagnoses, including VTE, misclassification may have occurred. In agreement with previous reports, 40, 41 approximately 89% of all VTE cases were confirmed with prescription and death records. Sensitivity analyses showed no evidence of differential misclassification, despite the somewhat lower absolute rates. Second, outpatient diagnoses are registered only from 2001 onward. For this reason, some patients treated as disease-free may have had a VTE history at diagnosis. Risk estimates were, however, not materially different after the exclusion of patients with preexisting VTE. Third, body mass index was the only variable assessed after diagnosis. We cannot rule out postdiagnostic changes in body mass index, but class effects are considered unlikely. The observed association with being overweight is also consistent with previous data. 10 Finally, it should be noted that cancer patients are subject to increased medical surveillance. This could have resulted in inflated HRs close to diagnosis, but long term risk estimates are less likely to be subjected to this type of bias.
In conclusion, our study confirms the long-term VTE risk in breast cancer patients and identifies a comprehensive set of clinical risk predictors that may facilitate future risk stratification and prevention efforts. Our findings also provide novel insights into the time-dependent etiology of VTE in breast cancer patients and underscore the importance of early-and late-onset differentiation in VTE risk prediction.
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